ASH 2020 – Forma gets an early edge over Agios in sickle cell disease

In the battle of the pyruvate kinase R activators in sickle cell disease, Forma Therapeutics has drawn first blood. Early data with the group’s FT-4202, presented at Ash today, suggest that the company has blown its rival Agios out of the water in terms of haemoglobin response.